SlideShare a Scribd company logo
2
Most read
3
Most read
6
Most read
TOXIC STUDIES
K V GOPINATH M Pharm PhD,CPhT
Tirumala Tirupati Devasthanams
TIRUPATI
e-mail:gopinath.karnam@gmail.com
Definitions
 Toxicity : Any toxic (adverse) effect that a chemical or physical
agent might produce within a living organism.
 Toxicology
Types of Toxic Studies
 Acute toxicity : It refers to those adverse effects occurring
following oral or dermal administration of a single dose of a
substance, or multiple doses given within 24 hours, or an inhalation
exposure of 4 hours.
 Sub acute Toxicity: It resembles acute toxicity except that the
exposure duration is greater, from several days to one month.
 Sub chronic toxicity: It is the toxic exposures repeated or spread
over an intermediate time range (1 – 3 months)
 Chronic Toxicity: It is the exposures (either repeated or
continuous) over a long (greater than 3 months) period of time.
SINGLE DOSE ACUTE TOXICITY
TESTING FOR PHARMACEUTICALS
INTRODUCTION
 Acute toxicity studies in animals are usually necessary for any
pharmaceutical intended for human use.
 It is useful in choosing doses for repeat-dose studies, providing
preliminary identification of target organs of toxicity, and,
occasionally, revealing delayed toxicity.
 Acute toxicity studies may also aid in the selection of starting doses
for Phase 1 human studies, and provide information relevant to acute
overdosing in humans.
DEFINITION
 Acute toxicity is the toxicity produced by a pharmaceutical when it is
administered in one or more doses during a period not exceeding 24
hours.
TESTING PROCEDURES
 The test compound should be administered to animals to identify
doses causing no adverse effect and doses causing major (life-
threatening) toxicity.
 The use of vehicle control groups should be considered
 Acute toxicity studies in animals should ordinarily be conducted
using two routes of drug administration: (1) The route intended for
human administration, and (2) intravenous administration, if feasible.
 Studies should be conducted in at least two mammalian species
(Rodents and non rodents)
CLASSIFICATION CRITERIA FOR
SUBSTANCES
Exposure Route Exposure Route 1
Category 1
Exposure Route
Category 2
Exposure Route
Category 3
Exposure Route
Category 4
Exposure Route
Category 5
Oral
(mg/kg)
5 50 300 2000 5000
Dermal
(mg/kg)
50 200 1000 2000
Gases
(PPM)
100 500 2500 5000
Vapours
Mg/l
0.5 2 10 20
Dusts &
Mists
0.05 0.5 1.0 5.0
OBSERVATION
 Animals should be observed for 14 days after pharmaceutical
administration. All mortalities, clinical signs, time of onset, duration,
should be recorded.
 Also reversibility of toxicity should be recorded.
 Gross necropsies should be performed on all animals, including those
sacrificed, moribund, found dead, or terminated at 14 days.
 Clinical pathology and histopathology should be monitored at an
early time and at termination (i.e., ideally, for maximum effect and
recovery).
 The toxicity studies should be designed to assess dose-response
relationships and pharmacokinetics to develop the lead compound.
CHRONIC TOXICITY STUDIES
 It is the ability of the substance or mixture of substances to cause
harmful effects over an extended period, usually upon repeated and
continuous exposure.
 The result of chronic toxicity study in animals should suggest signs
and symptoms of adverse reactions to look for in man.
PRINCIPLE OF TOXICITY STUDIES
 PRINCIPLE OF TOXICITY STUDIES
- Standard operating procedures (SOP’s) and NIH guidelines
should be thoroughly followed for these studies.
- It should be performed by well trained and qualified staff. -
- These should comply with norms of good laboratory
practices. - The test substances and systems should be properly
characterized and standardized.
 ANIMAL PROTECTION Studies should be designed so that the
maximum amount of information is obtained from the smallest
number of animals
 To avoid causing excessive pain or tissue damage in the animals,
pharmaceuticals with irritant or corrosive characteristics should not
be administered in concentrations that produce severe toxicity solely
from local effects.
Proposals For Clinical Study
Certain basic studies should be considered mandatory when
examining drug action in vivo
1. Make an assessment of drug exposure in the animal, preferably by
measurement of plasma drug concentrations at several time
points, and after several different doses.
2. Perform a measurement of the degree of plasma protein binding
of the drug, ex vivo if possible, and if not, then in vitro. This is vital
if comparisons are to be made of a drug action in more than one
species.
3. Obtain knowledge on the metabolism of the drug and determine
whether active metabolites could be influencing the results being
obtained.
Proposals For Clinical Study
4. Ensure that the dose schedules to be used are relevant to the way
that the drug will be used in humans to allow translational value to
the clinic.
5. Consider whether there is a temporal mismatch between the
exposure information being gained and the outcome measure being
investigated because this might give insight into the mechanism of
action of the compound under investigation.
6. Consider the determinants of target engagement whenever the
information above has been gathered.
Toxic studies

More Related Content

PPTX
ACUTE, SUB ACUTE & CHRONIC TOXICOLOGICAL STUDIES
PPTX
Subacute toxicity
PPTX
Tocixity studies
PPT
Poisoning & its management
PDF
Assignment on Toxicology
PPTX
Toxicity studies
PPTX
UV visible Spectroscopy
PPTX
Molecular modelling
ACUTE, SUB ACUTE & CHRONIC TOXICOLOGICAL STUDIES
Subacute toxicity
Tocixity studies
Poisoning & its management
Assignment on Toxicology
Toxicity studies
UV visible Spectroscopy
Molecular modelling

What's hot (20)

PPTX
Toxicity studies
PPTX
Poison information centre
PPTX
chronic toxicity studies
PPTX
Toxicological screening
PPTX
Acute, sub acute toxic studies toxicology pharmacology
PPTX
Central Drug Testing Laboratories & Responsibilities
PPTX
Toxicity Studies
PPTX
Pre Clinical Studies
PPTX
immunostimulants
PPTX
Patient information leaflets
PPTX
Acute toxicity studies-425
PPTX
Health screening services
PPTX
Chronopharmacology
PPTX
Acute and chronic toxicity studies in animals
PPTX
Toxicoloy
PPT
Principles of toxicology
PPTX
" GENERIC MEDICINE''
PPTX
-ROLE OF PHARMACIST IN HOSPITAL PHARMACY.pptx
PPTX
Community pharmacy-Definition ,scope and Roles and responsibilities of commun...
PPTX
DRUG INFORMATION SERVICE AND DRUG INFORMATION BULLETIN
Toxicity studies
Poison information centre
chronic toxicity studies
Toxicological screening
Acute, sub acute toxic studies toxicology pharmacology
Central Drug Testing Laboratories & Responsibilities
Toxicity Studies
Pre Clinical Studies
immunostimulants
Patient information leaflets
Acute toxicity studies-425
Health screening services
Chronopharmacology
Acute and chronic toxicity studies in animals
Toxicoloy
Principles of toxicology
" GENERIC MEDICINE''
-ROLE OF PHARMACIST IN HOSPITAL PHARMACY.pptx
Community pharmacy-Definition ,scope and Roles and responsibilities of commun...
DRUG INFORMATION SERVICE AND DRUG INFORMATION BULLETIN
Ad

Viewers also liked (20)

PPT
Animal toxicology studies
PPTX
INTRODUCTION TO TOXICOLOGY
PPTX
animal toxicity studies
PPT
Introduction to General toxicology
PPTX
Routes of drug administration
PPTX
Chronic toxicity studies a brief outlook
PPTX
Toxicity Studies
PPTX
Routes of Administration Pharmacology
PPTX
Drug metabolism
PPTX
Radiation Cytotoxicity
PPTX
Amphibian Monitoring
PPTX
2016 Dal Human Genetics - Genomics in Medicine Lecture
PPT
Drug discovery By Neelima Sharma WCC chennai,neelima.sharma60@gmail.com
PPTX
Introduction to human genetic 2016
PDF
3D In Vitro Models for Drug Efficiency Testing
PDF
Merck Chemicals - Safety of LC Materials
PPTX
Finding and Accessing Human Genomics Datasets
PPTX
Invitro antidiabetic activity
PPT
s.s.c (Alternative to animal study)
PDF
Perfect sample preparation. Is complete and holistic extraction of odourants ...
Animal toxicology studies
INTRODUCTION TO TOXICOLOGY
animal toxicity studies
Introduction to General toxicology
Routes of drug administration
Chronic toxicity studies a brief outlook
Toxicity Studies
Routes of Administration Pharmacology
Drug metabolism
Radiation Cytotoxicity
Amphibian Monitoring
2016 Dal Human Genetics - Genomics in Medicine Lecture
Drug discovery By Neelima Sharma WCC chennai,neelima.sharma60@gmail.com
Introduction to human genetic 2016
3D In Vitro Models for Drug Efficiency Testing
Merck Chemicals - Safety of LC Materials
Finding and Accessing Human Genomics Datasets
Invitro antidiabetic activity
s.s.c (Alternative to animal study)
Perfect sample preparation. Is complete and holistic extraction of odourants ...
Ad

Similar to Toxic studies (20)

PPTX
Updates onAcute and Chronic Studies.pptx
PPTX
Chronic Toxicity Study (OECD TG-452).pptx
PPTX
Pharmacology -II(5 Unit)
PPT
Experimental Techniques For Evaluation Of New Drugs.ppt
PDF
Pre clinical studies
PPTX
OECD Guideline 420: Acute oral Toxicity - Fixed Dose Procedure
PPTX
Animal Toxicity Studies
PPTX
Toxicological approach for drug discovery
PPTX
Single dose and repeated dose toxicity studies.pptx
PPTX
Animal toxicity studies
PPT
Chapter 3.ppt.............................
PPT
Toxi chap 3.ppt
PPTX
Acute, sub-acute and Chronic oral studies (OECD).
PPTX
various approaches to drug discovery
PPTX
OECD 423 GUIDELINES AND COMPARISON WITH THE 420 AND 425.
PDF
toxicitytesting-200920120607.pdf
PPTX
Toxicity studies
PPTX
Animal toxicity.pptx
PDF
Toxicity testing
PPTX
OECD Guidelines
Updates onAcute and Chronic Studies.pptx
Chronic Toxicity Study (OECD TG-452).pptx
Pharmacology -II(5 Unit)
Experimental Techniques For Evaluation Of New Drugs.ppt
Pre clinical studies
OECD Guideline 420: Acute oral Toxicity - Fixed Dose Procedure
Animal Toxicity Studies
Toxicological approach for drug discovery
Single dose and repeated dose toxicity studies.pptx
Animal toxicity studies
Chapter 3.ppt.............................
Toxi chap 3.ppt
Acute, sub-acute and Chronic oral studies (OECD).
various approaches to drug discovery
OECD 423 GUIDELINES AND COMPARISON WITH THE 420 AND 425.
toxicitytesting-200920120607.pdf
Toxicity studies
Animal toxicity.pptx
Toxicity testing
OECD Guidelines

More from Nani Karnam Vinayakam (20)

PPTX
Introduction-to-Pharmacy-Business-Operations.pptx
PPTX
Cardio Pulmonary Resuscitation - CPR HandsTraining
PPT
International_Day_Against_Drug_Abuse__Illicit_Trafficking.ppt
PPT
Pharmacy always trusted for your health.ppt1234
PPT
PVPI _ A Cost Effective Programme For Patients
PPTX
Practical Approach of safe Disposal of Hospital Waste Management
PPTX
Pharmacy practice – a spiritual transformation
PDF
EVALUATION OF GLYCEMIC RESPONSE OF ADDITION OF PIOGLITAZONE TO GLIBENCLAMIDE...
PPT
X ray fluorescence (X R F)
PPT
Scanning Electron Microscope- Energy - Dispersive X -Ray Microanalysis (Sem E...
PPT
Pharmacy “it’s even more than you can imagine.”
PPT
Manufacture of sterile and nonsterile products
PPT
Asthma a clinical review and its management
PPT
Nano technology and its releavance to drug designing 08072013
PPT
New and traditional ayurvedic dosage forms
PPT
Analytical, toxicity, experimental and clinical validation of ayurvedic formu...
PPT
X ray diffraction
PPT
Thin Layer Chromatography and HighPerformance Thin Layer chromatography
PPT
Gas chromatography
PPT
Experimental and clinical validation of classical and proproetary ayurvedic f...
Introduction-to-Pharmacy-Business-Operations.pptx
Cardio Pulmonary Resuscitation - CPR HandsTraining
International_Day_Against_Drug_Abuse__Illicit_Trafficking.ppt
Pharmacy always trusted for your health.ppt1234
PVPI _ A Cost Effective Programme For Patients
Practical Approach of safe Disposal of Hospital Waste Management
Pharmacy practice – a spiritual transformation
EVALUATION OF GLYCEMIC RESPONSE OF ADDITION OF PIOGLITAZONE TO GLIBENCLAMIDE...
X ray fluorescence (X R F)
Scanning Electron Microscope- Energy - Dispersive X -Ray Microanalysis (Sem E...
Pharmacy “it’s even more than you can imagine.”
Manufacture of sterile and nonsterile products
Asthma a clinical review and its management
Nano technology and its releavance to drug designing 08072013
New and traditional ayurvedic dosage forms
Analytical, toxicity, experimental and clinical validation of ayurvedic formu...
X ray diffraction
Thin Layer Chromatography and HighPerformance Thin Layer chromatography
Gas chromatography
Experimental and clinical validation of classical and proproetary ayurvedic f...

Recently uploaded (20)

PPT
MENTAL HEALTH - NOTES.ppt for nursing students
PPTX
JUVENILE NASOPHARYNGEAL ANGIOFIBROMA.pptx
PPTX
Electromyography (EMG) in Physiotherapy: Principles, Procedure & Clinical App...
PDF
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
DOC
Adobe Premiere Pro CC Crack With Serial Key Full Free Download 2025
PDF
CT Anatomy for Radiotherapy.pdf eryuioooop
PPTX
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
PPTX
15.MENINGITIS AND ENCEPHALITIS-elias.pptx
DOCX
NEET PG 2025 | Pharmacology Recall: 20 High-Yield Questions Simplified
PDF
Handout_ NURS 220 Topic 10-Abnormal Pregnancy.pdf
PPTX
SKIN Anatomy and physiology and associated diseases
PPT
Breast Cancer management for medicsl student.ppt
PPTX
ACID BASE management, base deficit correction
PDF
Medical Evidence in the Criminal Justice Delivery System in.pdf
PPTX
CME 2 Acute Chest Pain preentation for education
PPTX
Fundamentals of human energy transfer .pptx
PDF
Human Health And Disease hggyutgghg .pdf
PPTX
1 General Principles of Radiotherapy.pptx
PPT
1b - INTRODUCTION TO EPIDEMIOLOGY (comm med).ppt
PPTX
Note on Abortion.pptx for the student note
MENTAL HEALTH - NOTES.ppt for nursing students
JUVENILE NASOPHARYNGEAL ANGIOFIBROMA.pptx
Electromyography (EMG) in Physiotherapy: Principles, Procedure & Clinical App...
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
Adobe Premiere Pro CC Crack With Serial Key Full Free Download 2025
CT Anatomy for Radiotherapy.pdf eryuioooop
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
15.MENINGITIS AND ENCEPHALITIS-elias.pptx
NEET PG 2025 | Pharmacology Recall: 20 High-Yield Questions Simplified
Handout_ NURS 220 Topic 10-Abnormal Pregnancy.pdf
SKIN Anatomy and physiology and associated diseases
Breast Cancer management for medicsl student.ppt
ACID BASE management, base deficit correction
Medical Evidence in the Criminal Justice Delivery System in.pdf
CME 2 Acute Chest Pain preentation for education
Fundamentals of human energy transfer .pptx
Human Health And Disease hggyutgghg .pdf
1 General Principles of Radiotherapy.pptx
1b - INTRODUCTION TO EPIDEMIOLOGY (comm med).ppt
Note on Abortion.pptx for the student note

Toxic studies

  • 1. TOXIC STUDIES K V GOPINATH M Pharm PhD,CPhT Tirumala Tirupati Devasthanams TIRUPATI e-mail:gopinath.karnam@gmail.com
  • 2. Definitions  Toxicity : Any toxic (adverse) effect that a chemical or physical agent might produce within a living organism.  Toxicology Types of Toxic Studies  Acute toxicity : It refers to those adverse effects occurring following oral or dermal administration of a single dose of a substance, or multiple doses given within 24 hours, or an inhalation exposure of 4 hours.  Sub acute Toxicity: It resembles acute toxicity except that the exposure duration is greater, from several days to one month.  Sub chronic toxicity: It is the toxic exposures repeated or spread over an intermediate time range (1 – 3 months)  Chronic Toxicity: It is the exposures (either repeated or continuous) over a long (greater than 3 months) period of time.
  • 3. SINGLE DOSE ACUTE TOXICITY TESTING FOR PHARMACEUTICALS INTRODUCTION  Acute toxicity studies in animals are usually necessary for any pharmaceutical intended for human use.  It is useful in choosing doses for repeat-dose studies, providing preliminary identification of target organs of toxicity, and, occasionally, revealing delayed toxicity.  Acute toxicity studies may also aid in the selection of starting doses for Phase 1 human studies, and provide information relevant to acute overdosing in humans. DEFINITION  Acute toxicity is the toxicity produced by a pharmaceutical when it is administered in one or more doses during a period not exceeding 24 hours.
  • 4. TESTING PROCEDURES  The test compound should be administered to animals to identify doses causing no adverse effect and doses causing major (life- threatening) toxicity.  The use of vehicle control groups should be considered  Acute toxicity studies in animals should ordinarily be conducted using two routes of drug administration: (1) The route intended for human administration, and (2) intravenous administration, if feasible.  Studies should be conducted in at least two mammalian species (Rodents and non rodents)
  • 5. CLASSIFICATION CRITERIA FOR SUBSTANCES Exposure Route Exposure Route 1 Category 1 Exposure Route Category 2 Exposure Route Category 3 Exposure Route Category 4 Exposure Route Category 5 Oral (mg/kg) 5 50 300 2000 5000 Dermal (mg/kg) 50 200 1000 2000 Gases (PPM) 100 500 2500 5000 Vapours Mg/l 0.5 2 10 20 Dusts & Mists 0.05 0.5 1.0 5.0
  • 6. OBSERVATION  Animals should be observed for 14 days after pharmaceutical administration. All mortalities, clinical signs, time of onset, duration, should be recorded.  Also reversibility of toxicity should be recorded.  Gross necropsies should be performed on all animals, including those sacrificed, moribund, found dead, or terminated at 14 days.  Clinical pathology and histopathology should be monitored at an early time and at termination (i.e., ideally, for maximum effect and recovery).  The toxicity studies should be designed to assess dose-response relationships and pharmacokinetics to develop the lead compound.
  • 7. CHRONIC TOXICITY STUDIES  It is the ability of the substance or mixture of substances to cause harmful effects over an extended period, usually upon repeated and continuous exposure.  The result of chronic toxicity study in animals should suggest signs and symptoms of adverse reactions to look for in man.
  • 8. PRINCIPLE OF TOXICITY STUDIES  PRINCIPLE OF TOXICITY STUDIES - Standard operating procedures (SOP’s) and NIH guidelines should be thoroughly followed for these studies. - It should be performed by well trained and qualified staff. - - These should comply with norms of good laboratory practices. - The test substances and systems should be properly characterized and standardized.  ANIMAL PROTECTION Studies should be designed so that the maximum amount of information is obtained from the smallest number of animals  To avoid causing excessive pain or tissue damage in the animals, pharmaceuticals with irritant or corrosive characteristics should not be administered in concentrations that produce severe toxicity solely from local effects.
  • 9. Proposals For Clinical Study Certain basic studies should be considered mandatory when examining drug action in vivo 1. Make an assessment of drug exposure in the animal, preferably by measurement of plasma drug concentrations at several time points, and after several different doses. 2. Perform a measurement of the degree of plasma protein binding of the drug, ex vivo if possible, and if not, then in vitro. This is vital if comparisons are to be made of a drug action in more than one species. 3. Obtain knowledge on the metabolism of the drug and determine whether active metabolites could be influencing the results being obtained.
  • 10. Proposals For Clinical Study 4. Ensure that the dose schedules to be used are relevant to the way that the drug will be used in humans to allow translational value to the clinic. 5. Consider whether there is a temporal mismatch between the exposure information being gained and the outcome measure being investigated because this might give insight into the mechanism of action of the compound under investigation. 6. Consider the determinants of target engagement whenever the information above has been gathered.